🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Evaluating the Effectiveness of Intramuscular Versus Intravenous Tranexamic Acid for Minimizing Blood Loss After Total Hip Arthroplasty: A Randomized Controlled Trial

RecruitingEARLY Phase 1Ages 18 Years - anyAllAlexandria University
NCT07817537 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Intramuscular vs. Intravenous Tranexamic Acid for Total Hip Arthroplasty

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Adult patients aged 18 years and older. 2. Scheduled to undergo elective primary total hip arthroplasty. 3. Able to provide informed consent. Exclusion Criteria: * 1\. History of renal failure or kidney transplant. 2. History of an arterial thromboembolic event (such as myocardial infarction or stroke) within the past year. 3\. Placement of an arterial stent within the past year. 4. History of deep venous thrombosis (DVT) or pulmonary embolism (PE). 5. Known contraindications to tranexamic acid. 6. Pregnancy or breastfeeding. 7. Refusal to participate or refusal to consent to receive blood products.
💊

What it tests

  • Tranexamic Acid (TXA) intarmuscular
  • Tranexamic Acid (TXA) intravenous
📍

Where

1 site
Alexandria university main hospitals
Alexandria, Egypt
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy